Mode
Text Size
Log in / Sign up
Phase 4 N=100 Randomized Quadruple-blind Supportive Care

Intravenous Acetaminophen in Craniotomy

Postoperative Pain

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Jun 2018
Primary outcome: Primary: Post-Operative Opioid Requirement — 11.0; 10.1 Morphine Equivalents

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Acetaminophen (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
Mar 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Post-Operative Opioid Requirement
11.0; 10.1
SECONDARY
Post-Operative Pain
1.4; 2.6; 6.3; 6.4
SECONDARY
Post-Operative Side Effects
23; 20; 8; 5; 14; 14
SECONDARY
Time to Extubation at Emergence From Anesthesia
6; 8
SECONDARY
Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria
11.4; 13.5

Summary

The purpose of this study is to assess the use of intravenous Acetaminophen (OFIRMEV) as an effective adjunct therapeutic agent in patients undergoing craniotomy.

Eligibility Criteria

Inclusion Criteria

  • Adults
  • Undergoing Craniotomy for Supratentorial Tumor Resection
  • Weight between 50 and 120 kilograms
  • ASA Physical Status I-III
  • Be able to communicate verbally
  • Be able to use Visual Analog Score

Exclusion Criteria

  • Allergies to acetaminophen, morphine or any of the anesthetic agents required by the protocol.
  • Use of opioids, tramadol, benzodiazepines, or gabapentin on a daily basis for > 7 days prior to the day of surgery.
  • Use of acetaminophen, NSAIDs, or any other analgesic medication in the 12 hours immediately prior to study enrollment.
  • Hepatic insufficiency (elevated transaminases > 1.5 times the upper limit of normal) or renal insufficiency (plasma creatinine > 2mg/dl).
  • Known or suspected history of alcohol or illicit drug abuse.
  • Pregnant or breast-feeding.
  • Surgical plan for infratentorial (suboccipital) craniotomy.
  • Plan for neurophysiologic monitoring that precludes the use of neuromuscular blockade.
  • Inability to communicate due to a language barrier, impaired consciousness, cognitive defect or intellectual disability.
  • Uncontrolled Hypertension
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01598701). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search